2025-523460-21-00招募中2 期
A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 159
- 试验地点
- 5
- 主要终点
- Clinical Benefit Rate (CBR), defined as the proportion of patients achieving a Complete response (CR) or Partial response (PR) or Stable disease (SD) lasting at least 6 months, as assessed according to RECIST 1.1 criteria
研究概览
简要总结
Evaluation of a biomarker driven workflow for guiding clinical decision making in second line HR+/HER2- metastatic breast cancer
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female (both pre- and postmenopausal) patients with histologically confirmed diagnosis of adenocarcinoma of the breast with radiological evidence of metastatic disease
- •Women of childbearing potential must have a negative highly sensitive serum or urine pregnancy test within 7 days prior to randomisation.
- •Female subjects who are breast feeding should discontinue nursing during protocol treatment
- •Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained, and documented according to the local regulatory requirements
- •Estrogen Receptor (ER) and/or Progesteron Receptor (PgR) positive disease confirmed at immunohistochemistry (IHC), as either ER or PR expression ≥ 1%, at the time of metastatic diagnosis. Molecular assessment performed locally on either primary tumor tissue or a biopsy specimen from a metastatic site.
- •HER2 negative breast cancer by FISH or IHC (IHC 0, 1+, 2+ and/or FISH HER2: CEP17 ratio < 2.0) at the time of metastatic diagnosis.
- •Age at the time of signing the informed consent at least 18 years.
- •Disease progression after at least 6 months of first line endocrine therapy with CDK 4/6 inhibitors.
- •The patient must have evaluable disease according to RECIST 1.1 (either measurable or non-measurable)
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or
- •Adequate organ function (kidney, bone marrow and liver)
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of study drugs.
排除标准
- •Diagnosis of any secondary malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
- •Known hypersensitivity reaction to one of the compounds or substances used in this protocol
- •Pregnant women are excluded from the study
- •Previous or synchronous diagnosis of HER2-positive or triple-negative breast cancer
- •Prior chemotherapy for metastatic disease.
- •Disease progression before 6 months of first line endocrine therapy with CDK 4/6 inhibitors
- •Major surgery < 28 days before randomisation
- •Any unresolved toxic effect of prior therapies or surgical procedures of Grade ≥ 2 according to Common Terminology Criteria of Adverse Events (CTCAE v5.0), with the exception of alopecia, peripheral neuropathy and other toxicities not considered a safety risk for the participant at investigator’s discretion
- •Uncontrolled significant active infections (≥ grade 3 according to CTCAE version 5), including active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency Virus (HIV).
- •Uncontrolled intercurrent illness, including psychiatric conditions, that would, in the judgment of the investigator, limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
结局指标
主要结局
Clinical Benefit Rate (CBR), defined as the proportion of patients achieving a Complete response (CR) or Partial response (PR) or Stable disease (SD) lasting at least 6 months, as assessed according to RECIST 1.1 criteria
Clinical Benefit Rate (CBR), defined as the proportion of patients achieving a Complete response (CR) or Partial response (PR) or Stable disease (SD) lasting at least 6 months, as assessed according to RECIST 1.1 criteria
次要结局
- Progression Free Survival (PFS), defined as time from second line treatment start until progression or death for any cause, whichever comes first
- OS, defined as time from second line treatment start until death from any cause
- Prevalence of somatic alterations detected through plasma NGS in patients who are candidate to receiving second line therapy in HR+/HER2- MBC
- Prognostic impact on PFS and OS of somatic alterations detected through plasma NGS in patients candidate to receiving second line therapy in HR+/HER2- MBC
- Proportion of patients with a CTCs count ≥ 5/7.5 mL compared to those with a CTCs count <5/7.5 mL at baseline of second line therapy for HR+/HER2- MBC
- Prognostic impact on PFS and OS of a CTCs count ≥ 5/7.5 mL with respect to CTCs count < 5/7.5 mL in patients candidate to receiving second line therapy in HR+/HER2- MBC
研究者
Lorenzo Gerratana
Scientific
Centro Di Riferimento Oncologico Di Aviano
研究点 (5)
Loading locations...
相似试验
招募中
3 期
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.362025-522084-15-00IRCCS Istituto Nazionale Tumori Fondazione Pascale36
招募中
1 期
A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative CancerBreast CancerNCT07358377Atridia Pty Ltd.15
招募中
2 期
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyBreast CancerNCT07330544Zhejiang Cancer Hospital118
招募中
1 期
Biomarker analysis in patients with metastatic breast cancer treated with sacituzumab govitecan.male or pre/post-menopausal women age = 18 years with locally advanced/metastatic HR+/HER2-negative BC resistant to ET + CDK4/6 inhibitors. No more than 1 prior systemic chemotherapy or ADC regimens for metastatic disease are permitted.CTIS2023-505385-28-00Solti Group50
进行中（未招募）
2 期
Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute PancreatitisNCT07308392Fujian Shengdi Pharmaceutical Co., Ltd.119